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The aim of this study was to analyze adipose tissue-derived mesenchymal stem 
cells (AT-MSCs) using the Pap test as a first screening step to evaluate genetic 
stability. Human adipose tissue from six healthy female donors was obtained from 
elective liposuction procedures. The cells were isolated, cultivated at P2/P3, 
characterized by flow cytometric analysis, and differentiation induced. The AT-
MSCs were stained by Papanicolaou staining and analyzed according to the 
Bethesda classification, and viability-apoptosis relationships were evaluated. The 
results of the Pap test for Sample I indicated high-grade alterations consistent with 
genetic instability; for Samples II-V, atypical cells of undetermined significance; 
and for Sample VI, normal cells. These results demonstrate the potential of using 
the Pap test as an initial screening step to evaluate the genetic stability of cultured 
AT-MSCs and also suggest its use for other adherent cells such as embryonic stem 
cells or induced pluripotent stem cells. 
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The promise of stem cell-based therapy for advancement of research in regenerative 
medicine has stimulated a great number of clinical trials, particularly for previously 
untreatable diseases. This promise has been borne out in the twentieth century with 
good results obtained with bone-marrow transplantation for oncohematological diseases 
with the first successful allogeneic bone-marrow transplant by Georges Mathé (1958), 
and for illnesses other than cancer by Robert Alan Good (1968), and optimized since 
that time using modern approaches
1,2
. 
Meanwhile, stem cell preclinical studies in ischemic cardiomyopathy have 
demonstrated heart function improvement with cell-based therapy, and have shown 
benefits in other tissues such as the spinal cord; thus, it is vital to transfer these 
treatments to humans in a clinical therapeutic setting
3–6
. 
However, for new therapies, it is necessary to ensure the safety of processes and 
products in an efficient manner. Toward this aim, therapeutic use of biological products 
mandates the establishment and use of basic requirements known as Good Tissue 
Practices to prevent disease transmission, mix-ups, and cross-contamination, assuring 
safe cell therapy
7
. 
When stem cell therapy is used for oncohematological diseases with bone 
marrow-derived cell transplantation, the protocol is well established for using fresh 
bone marrow cells or mononuclear cells from cryopreserved umbilical cord blood for 
allogeneic transplantation or cryopreserved mononuclear cells from peripheral blood for 
autologous procedures. All these procedures are conducted without cell cultivation to 
avoid modified cells. These protocols are rigorously controlled by the International 
Society for Hematotherapy and Graft Engineering (ISHAGE, 
www.celltherapysociety.org). 
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As with oncohematological diseases, cell-based regenerative therapy is expected 
to be useful in nonhematological diseases with cells of adult origin, such as 
mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs); both cell 
types are self-renewing populations and have pluripotent capacities to regenerate 
various tissues: cartilage, bone, muscle tendons, and the nervous system
8,9
. The three 
characteristics that define MSCs are a) plastic-adherent growth, b) expansion as 
undifferentiated MSCs under specific culture conditions with a panel of specific surface 
antigens, and c) in vitro or in vivo differentiation potential
10
.  
MSCs could also be used for transplantation in cell-based therapy, and for this 
purpose, must be able to expand ex vivo under cultivation. They should be able to grow 
in flasks based in their characteristic of adherence to plastic. However, the literature has 
demonstrated that transplantation is limited by the number of MSCs; thus, better results 
are dependent on producing a great number of cells independent of their source and 
consequently, large numbers of cells are usually required for clinical applications. 
Transplantation is also limited by mortality of the transplanted cells after transplantation 
by apoptosis or macrophage activity independent of the autologous or allogeneic 
procedures used. For the same reasons, iPSCs must also undergo expansion under ex-
vivo conditions.  
These considerations highlight the need for the in vitro expansion of stem cells 
prior to their commitment into tissue-specific applications. Before bioreactors can be 
used, several factors must be considered, including the need to increase the number of 
cells, the capacity to support high cell densities in relatively small volumes, the ability 
to scale up the design, and standardization of the bioprocess, including the safety of the 
products
11
. 
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Difficulties have been reported during cultivation of MSCs for expansion. 
Spontaneous transformation of murine hematopoietic MSCs (mMSCs) has been 
described by many authors, although there are contradictory results
12,13
. However, 
another group observed spontaneous malignant transformation in a preclinical study in 
which the cells had modified characteristics after the third passage. Direct injection of 
cultured bone marrow-derived MSCs into immunocompetent mice has resulted in tumor 
formation, and a karyotype analysis showed that increased chromosome numbers and 
multiple Robertsonian translocations occurred at passage 3 coincident with the loss of 
contact inhibition
14,15
. On the other hand, spontaneous transformation over the long-
term in human MSCs (hMSCs) from bone marrow cultures has not been reported in 
other studies
16,17
. In humans, one group observed spontaneous malignant transformation 
of adipose tissue-derived (AT)-MSCs in vitro
18
.  
Ultimately, Røsland et al. (2009) conclusively demonstrated spontaneous 
malignant transformations in long-term cultured bone marrow-derived human MSCs 
(5–106 weeks)19. The possibility of cell modifications compromises the reproducibility 
and safety of generation of MSCs under standardized conditions. The consequence of 
these results was increased requirements to maintain safe cell therapy beyond the basic 
requirements and regulations of government health organizations to ensure the identity, 
purity, potency, and clinical efficacy of MSCs. 
The Center for Biologics Evaluation and Research (CBER; Rockville, MD, USA), 
one of seven centers of the United States Food and Drug Administration, has described 
its approach to the regulation of stem cells for clinical trials in the United States under 
the heading of ―human cells, tissues, and cellular and tissue-based products (HCT/Ps).‖  
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The protocol governs quality control of cells by the FDA, excluding genetically 
modified cells, and primarily addresses safety concerns with cell differentiation to 
undesired cell types and potential uncontrolled cell proliferation or tumorigenicity
20
. 
Others concerns about the safety of this type of therapy are related to the stability of the 
product and/or the cell line, specifically, the number of passages/doublings over time, 
and maintaining desired differentiation properties without karyotypic alterations
21
. 
Currently, there are no stem cell therapies licensed for use in the United States, 
but there are many investigational therapies currently undergoing clinical trials 
authorized by CBER. Many therapies under development by researchers are in the 
preclinical phase or phase I in the USA as well as in other countries. According to the 
FDA website, the total number of North American clinical studies is 2165 and only 63 
MSC-based therapies were in progress involving cell cultivation; these cells were from 
various tissues, including hematological, adipose, cornea, conjunctive, skeletal muscle, 
and oral mucosa 
22
. 
All of those proceedings impose great costs in translating these therapies to 
humans and barriers to democratization of advanced therapy approaches. If cell-based 
therapies could be made more efficient, more people could access their benefits; ideally, 
the cost of each step would be reduced, without prejudicing the safety of the therapy. 
In our laboratory, over the last eight years, we have made morphological 
observations of undifferentiated MSCs from human bone marrow and adipose tissue up 
to P5 (not for transplantation use), reviewing and recording a diary of cultured cells 
using an inverted microscope for the purposes of research academics. We have observed 
some issues that would be of concern regarding the health of cultured MSCs for 
potential use in transplantation cell-based therapy. In developing countries, particularly 
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in Brazil where our group is established, we have limited financial resources and at 
times, we need to answer certain questions without great cost. Why not ―do simple 
things in a simple way‖23? 
With that concept in mind, we chose the Papanicolaou test, known as the Pap 
smear or cervical smear, a cytological analysis of exfoliated cells from the cervix 
originally described by George Papanikolaou in 1928
24
. This test is efficient in 
diagnosing early abnormal changes in the cervical epithelium that could indicate the 
presence of cervical cancer, and is universally used for screening for cervical cancer in 
woman
25
. Changes due to technological developments in other areas of science have 
resulted in significant increases in efficiency since the Pap test was first developed.  
The possibility of analyzing cultured MSCs at low cost using the Pap test appears very 
attractive to avoid additional steps, as a first step why it is a simple and short procedure 
requiring laboratory equipment available to everyone, in contrast to the more 
cumbersome trial procedures required by the FDA, if,  similar abnormalities as for 
squamous cells of the cervix can be demonstrated. The aim of this study was to analyze 
AT-MSCs using the Pap test. 
 
RESULTS 
Table 1 shows the results of the flow cytometric analysis for Samples I-VI, as well the 
viability/apoptosis relationships. The obtained cells were demonstrated to be MSCs 
from adipose tissue why the cells were marked with antibodies that are in consensus of 
adipose origin as well the cells were integrity preservation demonstrates by great 
viability and small apoptosis fraction; all samples have demonstrated the normal profile 
of undifferentiated adipose derived stem cells (Fig. 1), the cells were adherents and all 
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samples were capable of differentiation in lipid cells demonstrated by oil Sudan red and 
bone by alizarin osseous matrix identification, respectively (Fig. 2). The Pap test for 
Sample I showed high-grade alterations consistent with genetic instability (Fig. 3,4), 
Samples II-V contained atypical cells of undetermined significance (Figs. 5,6) and 
Sample VI comprised normal cells (Fig. 7).  
 
DISCUSSION 
These results demonstrate the potential for using the Pap test as the initial step of 
a screening methodology to ensure the genetic stability of cultured MSCs. As described 
by various authors, the difficulty in assuring accuracy in the Pap test is more in the 
preparation of cervical smears than in the analysis, because it is possible to use 
rescreening methods for negative results
26–28
.  
It is much easier to obtain a thin and clean smear starting from a cell culture than 
from the cervical samples normally used in a conventional Pap test. It is therefore 
possible that the efficiency and accuracy of a Pap test to detect changes in cells from 
culture would be greater than in cervical cancer screening programs. The Pap test is 
used to differentiate cells in many types of specimens: cerebrospinal, abdominal, or 
pleural fluids; synovial tissues; tumor samples; or other materials containing cells
26–28
.  
The cytopathological findings for the AT-MSC samples in this study may be 
explained by suppression of RNA polymerase II serine-2 phosphorylation. This 
suggests a conserved mechanism of transcriptional quiescence in various stem cells and, 
in the absence of telomerase expression, why AT has a slow turnover and AT-MSCs 
participate in tissue homeostasis and respond to tissue injury, but stay in a quiescent 
form prior to injury longer than others
30,31
.  
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The AT is ―aged‖—the differentiated adipocytes as well their quiescent AT-MSCs 
—and these cells are likely at increased risk of genetic instability. The adult MSCs were 
demonstrated to differentiate in varying concentrations in both solid and hematopoietic 
tissues in blood suspension; however, while the pluripotentiality of AT-MSCs may be 
similar to those of hematopoietic origin, their genetic stability may not be
32,33
. The 
abnormality findings in a previous study of AT-MSCs suggest that inclusion of the Pap 
test for both allogeneic and autologous donors would be valuable, because abnormalities 
may develop in cultured cells independent of the type of donor
34
. 
These finding suggests that the Pap test could be used not only for adult sources, 
but also for all adherent cells from embryos, fetuses, and adult tissue such as iPSCs or 
MSCs. The results of our study demonstrate the usefulness of the Pap test as the initial 
quality control step for cultured stem cell therapy, independent of the origin, source, or 
type of transplantation. This approach seems reasonable if identification of modified 
cells in this first step could avoid additional costs. If modified cells were present at this 
first step, they would not be considered safe for use in transplantation. The atypical cells 
and cells of unknown significance are not safe; they may not be pathogenic, but they 
may transform to cancer stem cells. Caution is required and the risk is not considered 
acceptable. If there were no modified cells according to the Pap test results, the next 
step of the screening procedure involving the karyotype analysis would be followed.  
The limitations of this study were the small sample size evaluated, nevertheless 
the intention was not statistical approach to do as well this study have not made in vivo 
transplantation of those cells to nonobese diabetic or severe combined immunodeficient 
mice to test the sequence of the genetic instability for the sample with high-grade 
alterations. These results of "undetermined significance" should be followed up in 
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further studies. How would this affect the usefulness of those cells to obligate to 
discharge or go to the next step of the screening? This study has not proposed to answer 
that question. 
Tsuji et al. (2010) has suggested with respect to iPSC transplantation that to await 
the results of injecting cells into mice and subsequent tumor development to exclude 
cells for transplantation after two months will increase the delay in deciding whether to 
use the cells
29
. We concur, and further suggest that our results support the proposition to 
introduce the Pap test into the algorithm for screening cell modification as an initial step 
(Fig. 08). To contribute for the usefulness of this test as a screening step is the 
possibilities to exclude in the start of screening the cells that have definite and 
indubitable high-grade alterations.  
  
ACKNOWLEDGMENTS 
Financial support was received from Coordination for the Improvement of Higher Level -or Education- 
Personnel (CAPES) for Post-Graduation Student Grants.  
COMPETING FINANCIAL INTERESTS 
The authors declare that they have no competing financial interests. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.5
67
6.
1 
: P
os
te
d 
14
 F
eb
 2
01
1
 12 
 
Figure Legends 
  
Figure 1 Four-color staining immunophenotyping analyses of Sample I. The following 
rat antibody conjugates, coupled with fluorescein isothiocyanate (FITC), phycoerythrin 
(PE), CyChrome (PE-Cy5), or allophycocyanin (APC) were used: CD45-PE-Cy5 (clone 
HI30), CD34-FITC (clone 581), CD49d-PE-Cy5 (clone 9F10), CD105-FITC (clone 
266), CD73-PE (clone AD2), CD90-FITC (clone 5E10), and conjugated 7AD-annexin 
(Becton Dickinson). The respective isotype matched control was PE MoAb.  
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Figure 2 Differentiated adipose tissue mesenchymal stem cells (AT-MSCs). Clones 
were stained with alizarin for osteogenesis and Oil Red O for adipogenesis. Samples I 
(above) and their controls (below), respectively. 
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Figure 3 Pap test results, Sample I, human AT-MSCs. Papanicolaou stain, P2, 100 
optical microscopy. (a) Cells with atypical mitosis (arrows) and (b) cell with an 
increased number of nuclei (arrow). The analysis result according to the Bethesda 
classification was high-grade alterations consistent with genetic instability. 
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Figure 4 Pap test results, Sample I, human AT-MSCs. Papanicolaou stain, P2, 100 
optical microscopy. (a) Cell with an increased number of nuclei (arrow) and (b) cell 
with an atypical and multilobulated nucleus (arrow). The analysis result according to the 
Bethesda classification was high-grade alterations consistent with genetic instability. 
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Figure 5 Pap test results, Sample III, human AT-MSCs. Papanicolaou stain, P2, 100 
optical microscopy. (a) Cell with a nucleus of increased size (arrow) and (b) cells with 
morphological normal aspects (arrow). The analysis result according to the Bethesda 
classification was atypical cells of undetermined significance. 
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Figure 6 Pap test results, Sample IV, human AT-MSCs. Papanicolaou stain, P2, 100 
optical microscopy. (a) Cell with a double nucleus (arrow) and (b) cells with normal 
morphological aspects.  The analysis result according to the Bethesda classification was 
atypical cells of undetermined significance. Na
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Figure 7 Pap test results, Sample VI, human AT-MSCs. Papanicolaou stain, P2, 100 
optical microscopy. (a) Cells with normal morphological aspects. Typical mitosis in 
telophase (arrow) and (b) Cells with normal morphological aspects. Typical mitosis in 
anaphase (arrow). The analysis result according to the Bethesda classification was 
normal cells. 
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Figure 8 Algorithm for screening cell modifications beginning with the Pap test. 
 
 
 
 
 
METHODS 
Isolation of adipose tissue-derived MSCs 
Human abdominal AT from six healthy female donors was obtained and designated 
Samples I–VI (ages 47, 38, 24, 45, 35, and 41 years with body-mass index 22.3, 29.4, 
24.7, 29.4, 22.8, and 23.6, respectively). Samples were obtained during elective 
liposuction procedures for plastic and cosmetic purposes under local anesthesia after 
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informed consent, following the guidelines of the Brazilian Ethics Committee on Use of 
Human Subjects and as approved by the Pequeno Príncipe Hospital Complex Ethics 
Committee, number 0617-08. 
The AT-MSCs were isolated in accordance with Zuk et al. (2001)
35
. The 
lipoaspirates were washed extensively with sterile PBS to remove contaminating debris 
and red blood cells. The washed aspirates were treated with 0.075% collagenase (type I, 
Sigma) in PBS for 30 minutes at 37 °C with gentle agitation. The collagenase was 
inactivated with an equal volume of DMEM/10% FBS and the pellet was centrifuged 
for 10 minutes at low speed before being resuspended in DMEM/F12/10% FBS with 
1% antibiotic and filtered through a 100-μm mesh filter to remove debris. The filtrate 
was centrifuged and plated onto conventional tissue culture plates and the samples were 
then characterized by flow cytometric analysis. 
 
Cell characterization and viability–apoptosis relationships 
Flow cytometric analysis (FACScalibur; Becton Dickinson) was performed to validate 
the MSCs from adipose tissue. The harvested cells from the culture dishes underwent 
flow cytometric analysis to characterize the immunophenotypic profile of cellular 
subsets using the surface markers CD45, CD34, CD49d, CD73, CD90, and CD105.  
Viability–apoptosis relationships were characterized using conjugated 7AD-
annexin. The procedure used was ―stain then lyse;‖ lysis was performed after staining 
with monoclonal antibodies (MAb). The cells were incubated with the specific MAb 
panel for 15 minutes at room temperature in the dark, lysed (FACS lysing solution, 
Becton Dickinson), washed with 0.1% PBS, resuspended, and analyzed on a 
FACScalibur using CellQuest software (Becton Dickinson). 
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For the 4-color staining immunophenotyping analyses, the following rat antibody 
conjugates, coupled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), 
CyChrome (PE-Cy5), or allophycocyanin (APC) were used: CD45-PE-Cy5 (clone 
HI30), CD34-FITC (clone 581), CD49d-PE-Cy5 (clone 9F10), CD105-FITC (clone 
266), CD73-PE (clone AD2), and CD90-FITC (clone 5E10). All antibodies were used at 
the concentrations recommended by the manufacturer. The respective isotype-matched 
control was PE MoAb. 
 
Induced differentiation 
Differentiated AT-MSCs and their clones were processed as described in Zuk et al. 
(2002)
36
. Briefly, the AT-MSCs were washed extensively with sterile PBS to remove 
contaminating debris and were cultured in induction medium (DMEM/F12 and 10% 
FBS supplemented with the growth factors for each cell type: for adipogenic, 0.01 μM 
1,25-dihydroxyvitamin D3, 50 μM ascorbate-2-phosphate, 10 mM β-glycerophosphate, 
and 1% antibiotic; and for osteogenic, 0.5 mM isobutyl-methylxanthine, 1 μM 
dexamethasone, 10 μM insulin, 200 μM indomethacin, and 1% antibiotic). 
 
Cytology and immunocytochemistry 
Differentiated AT-MSCs and their clones were stained for the assays with alizarin for 
osteogenesis and oil Sudan for adipogenesis. 
 
Papanicolaou staining 
The Pap test is based on specific changes in the cytoplasm and/or nucleus of the 
epithelial cells of the cervix, which can be identified through light microscopy. In this 
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method, the sample cells are placed in a thin and uniform layer on cleaned and 
degreased glass slides, known as ―conventional smears‖. These smears are submersed in 
a fixative solution (usually absolute ethyl alcohol) and then colored. A combination of 
two coloring agents is used: a nuclear dye, Harris hematoxylin; and a mixture of two 
cytoplasmatic dyes, orange G and polychrome mixture (EA51)
37
.  
This dye combination highlights cellular aspects that are fundamental in 
differentiating normal squamous cells of the cervix from low- and high-grade squamous 
intraepithelial lesions (LSILs and HSILs, respectively)
38
. These aspects include nuclear 
pigmentation, position, volume, and morphology; membrane regularity and integrity; 
and the chromatin arrangement. Other important parameters are the cellular size and 
shape, and the ratio of the nucleus to the cytoplasm, which is increased in pre-cancerous 
cells
26,39
. 
In this study, the AT-MSCs were seeded in 25-cm
2
 flasks at 5  104/mL, then cultured 
for 7–14 days to P2 and P3 until 70% confluence was reached. The cells were then 
cultured for three days on double-chamber slides, after which the cultures were ended 
and the stain applied directly to the slides. Undifferentiated AT-MSCs were stained by 
Papanicolaou staining. Each slide was immersed in vats containing the staining 
solutions in sequence for the appropriate immersion times in accordance with the 
manufacturer’s instructions (Newprov, Pinhais, Brazil). The slides were then mounted 
and observed under a light microscope. The analysis result was determined in 
accordance with the Bethesda classification as (a) normal cells, (b) atypical cells of 
undetermined significance, or (c) high-grade alterations consistent with genetic 
instability
38,39
. 
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Table 1. Immunophenotypic expression by flow cytometric analysis (%)  
AT-MSC CD34- CD45- CD49d+ CD73+ CD90+ CD105+ ANNEXIN- 7-AAD- 
I (a) 99.64 99.43 84.07 99.58 99.67 98.55 95.59 95.02 
II (b) 99.64 99.83 96.38 99.84 99.95 99.41 93.52 91.57 
III (c) 98.81 99.99 94.09 99.12 99.52 99.84 86.31 87.02 
IV (d) 96.68 99.85 93.74 99.66 99.86 99.80 95.22 92.65 
V (e) 99.19 99.88 88.77 99.88 99.87 99.91 96.20 94.22 
VI (f) 97.04 99.91 81.24 99.45 99.86 99.20 90.40 95.17 
AT-MSC: adipose-tissue mesenchymal stem cells; CD34: CD34-FITC (clone 581); CD45: 
CD45-PE-Cy5 (Clone HI30); CD49d: CD49d-PE-Cy5 (clone 9F10); CD73: CD73-PE (clone 
AD2); CD90: CD90-FITC (clone 5E10); CD105: CD105-FITC (clone 266); 7- 
AAD: conjugated 7AD-annexin; -: negative expression; +: positive expression. 
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